trial

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

NCTId NCT01959594
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 40 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2014-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2013-11
Primary completion
2014-03
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
3 mg PF-0641256210 mg PF-0641256225 mg PF-06412562PF-06412562 TBD mg
Indications
Healthy

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE1
Primary Completion Date
2014-03
Status
COMPLETED
relationships
The graph out of here
drug
3 mg PF-06412562
drug
10 mg PF-06412562
drug
25 mg PF-06412562
drug
PF-06412562 TBD mg
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Healthy
indication